II. Indications

  1. Type II Diabetes Mellitus
    1. Especially in Obesity
    2. May be used in combination with basal Insulin (e.g. Lantus)
  2. Insulin deficiency and Insulin Resistance
    1. Adjunct to Glucophage, Sulfonylureas, Glitazones

III. Contraindications

  1. Type I Diabetes Mellitus
  2. Concurrent prandial Insulin (bolus Insulin)
    1. Basal Insulin (e.g. Lantus) may be used with Byetta
  3. Renal Failure: Creatinine Clearance <30 ml/min

IV. Mechanism

  1. Synthetic form of exendin-4
    1. Originally identified in Gila Monster Saliva
    2. Peptide with 39 amino acids
  2. Incretin Mimetic
    1. Incretin analogue that mimics endogenous hormone
    2. Incretin released from GI tract following meals
  3. Incretin effects
    1. Increases Glucose dependent Insulin secretion
    2. Delays gastric emptying
    3. Decreases food intake (improves satiety)

V. Preparations

  1. Exenatide (Byetta)
    1. Glucagon-Like Peptide 1 (GLP-1) agonist derived from Gila monster Saliva
    2. Associated with weight loss and Nausea
  2. Exenatide Weekly (Bydureon)
    1. Injected once weekly
    2. More effective than Byetta and as effectiev as Victoza
    3. Less Nausea than Byetta or Victoza
    4. Requires reconstitution from powder before dose
  3. Liraglutide (Victoza)
    1. Single daily injection (as contrasted with twice daily Byetta)
    2. More potent than Byetta in lowering Hemoglobin A1C and similar efficacy to
    3. Adverse effects include Nausea (transient) and Headache

VI. Dosing: Byetta

  1. Initial
    1. Byetta 5 mcg SQ twice daily
    2. Give within 60 minutes of morning and evening meals
  2. Later, if Blood Sugars not optimized
    1. May increase to 10 mcg bid after 1 month
  3. Preparations: Prefilled pen holds 30 day supply
    1. 5 mcg/dose pen holds 1.2 ml of 250 mcg/ml
    2. 10 mcg/dose pen holds 2.4 ml of 250 mcg/ml

VII. Efficacy

  1. Lowers HBA1C 0.4 to 0.8% (at 5 and 10 mcg doses)
  2. Lowers weight by up to 4-10 pounds

VIII. Cost

  1. Monthly: $340 per month

IX. Adverse effects: Byetta

  1. Nausea (44%) or Vomiting (13%)
    1. Less frequent with Bydureon
  2. Diarrhea (13%)
  3. Dizziness (9%)
  4. Headache (9%)
  5. Hypoglycemia
    1. With Sulfonylurea: 14.4% at 5 mcg, 35.7% at 10 mcg
    2. With Glucophage: 4.5% at 5 mcg, 5.3% at 10 mcg
  6. Pancreatitis
    1. Incidence may be as high as 1 in 50 on Byetta for two years
    2. Singh (2013) JAMA Intern Med 173(7):534-9

X. Precautions

  1. Avoid using 2 Incretins (e.g. Byetta with Januvia) in combination (raises cost, risk of Pancreatitis without significant benefit)
  2. (2012) Presc Lett 19(8): 45

Images: Related links to external sites (from Google)

Cost: Medications

Byetta 5 MCG Pen (on 2/9/2012 at DrugStore.com)
Byetta 5 MCG Pen 5mcg/0.02ml Solution 1.2ml Pen #1 for $337.00 ($337.00/unit)
Byetta 10 MCG Pen (on 2/9/2012 at DrugStore.com)
Byetta 10 MCG Pen 10mcg/0.04ml Solution 2.4ml Pen #1 for $281.98 ($281.98/unit)
Victoza (on 2/9/2012 at DrugStore.com)
Victoza 18mg/3ml Solution 1 Box Contains Two 3ml Pens #1 for $325.98 ($325.98/unit)
Victoza 18mg/3ml Solution 1 Box Contains Three 3ml Pens #1 for $462.99 ($462.99/unit)

Ontology: exenatide (C0167117)

Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance(T121)
MSH C074031
SnomedCT 416859008, 417734003
English exendin-4, EXENATIDE, exenatide (medication), exenatide [Chemical/Ingredient], Ex4 peptide, exendin 4, exenatide, Exendin 4, Exenatide (product), Exenatide (substance), Exenatide
Spanish exenatida (producto), exenatida (sustancia), exenatida

Ontology: Byetta (C1636686)

Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance(T121)
MSH C074031
English Byetta